Innova Captab Limited - Asset Resilience Ratio
Innova Captab Limited (INNOVACAP) has an Asset Resilience Ratio of 2.25% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2026)
This chart shows how Innova Captab Limited's Asset Resilience Ratio has changed over time. See INNOVACAP financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Innova Captab Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Innova Captab Limited worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs412.85 Million | 2.25% |
| Total Liquid Assets | Rs412.85 Million | 2.25% |
Asset Resilience Insights
- Limited Liquidity: Innova Captab Limited maintains only 2.25% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Innova Captab Limited Industry Peers by Asset Resilience Ratio
Compare Innova Captab Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401 |
Drug Manufacturers - Specialty & Generic | 5.09% |
|
KPC Pharmaceuticals Inc
SHG:600422 |
Drug Manufacturers - Specialty & Generic | 16.37% |
Annual Asset Resilience Ratio for Innova Captab Limited (2019–2026)
The table below shows the annual Asset Resilience Ratio data for Innova Captab Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 2.25% | Rs412.85 Million ≈ $4.46 Million |
Rs18.37 Billion ≈ $198.71 Million |
-0.90pp |
| 2025-03-31 | 3.15% | Rs497.62 Million ≈ $5.38 Million |
Rs15.80 Billion ≈ $170.92 Million |
-2.33pp |
| 2024-03-31 | 5.48% | Rs723.64 Million ≈ $7.83 Million |
Rs13.21 Billion ≈ $142.85 Million |
+5.13pp |
| 2023-03-31 | 0.34% | Rs35.00 Million ≈ $378.51K |
Rs10.19 Billion ≈ $110.17 Million |
+0.22pp |
| 2022-03-31 | 0.13% | Rs7.23 Million ≈ $78.19K |
Rs5.75 Billion ≈ $62.24 Million |
-1.80pp |
| 2021-03-31 | 1.92% | Rs70.99 Million ≈ $767.73K |
Rs3.70 Billion ≈ $39.97 Million |
+0.62pp |
| 2020-03-31 | 1.30% | Rs49.45 Million ≈ $534.78K |
Rs3.80 Billion ≈ $41.08 Million |
+0.39pp |
| 2019-03-31 | 0.92% | Rs30.12 Million ≈ $325.74K |
Rs3.29 Billion ≈ $35.53 Million |
-- |
About Innova Captab Limited
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhib… Read more